STOCK TITAN

ParkerVision (OTCQB: PRKR) registers 1.578M shares; warrants could yield $526K

(Neutral)
(Neutral)
Form Type
424B3

Rhea-AI Filing Summary

ParkerVision, Inc. is updating its resale prospectus to cover 1,578,946 shares of Common Stock available for resale by a selling stockholder, consisting of 1,052,631 shares and 526,315 shares issuable upon exercise of related warrants. The company will not receive proceeds from the resale; if the Warrants are exercised for cash, the company would receive up to $526,315. The supplement attaches a Form 8-K filed April 27, 2026 and also discloses that the Compensation Committee extended certain executive stock options' expiration dates to August 7, 2029, with an expected one-time non-cash share-based charge of approximately $360,000.

Positive

  • None.

Negative

  • None.

Insights

Resale registration rather than new primary financing; warrant exercises could yield modest cash.

The prospectus supplement registers 1,578,946 shares for resale by a selling stockholder, including 526,315 shares underlying warrants exercisable for cash. The company states it will receive proceeds only if those warrants are exercised, up to $526,315. Cash inflows therefore depend on holder exercise decisions rather than company sales.

Timing and likelihood of exercise are not stated; subsequent filings would be required to show actual proceeds or exercises.

Executive option extensions create a one-time non-cash charge but do not issue new shares now.

The Compensation Committee extended expiration dates for options granted August 7, 2019: 2,660,000 options (CEO) and 870,550 options (CFO) from their original 2026 expiry to August 7, 2029. The company expects a one-time, non-cash share-based compensation charge of approximately $360,000.

No change was made to exercise price $0.171, vested status, or share counts; no securities were issued in connection with the modification.

Registered shares 1,578,946 shares Prospectus Supplement dated <date>April 27, 2026</date>
Breakdown - issued shares 1,052,631 shares Part of the 1,578,946 registered for resale
Breakdown - warrant shares 526,315 shares Shares underlying Warrants from SPA dated <date>December 14, 2021</date>
Potential cash from warrant exercises <money>$526,315</money> If the 526,315 Warrants are exercised for cash
CEO options 2,660,000 options Options originally awarded August 7, 2019; expiration extended to <date>August 7, 2029</date>
CFO options 870,550 options Options originally awarded August 7, 2019; expiration extended to <date>August 7, 2029</date>
Expected non-cash charge <money>$360,000</money> One-time share-based compensation charge related to option modification
Option exercise price <money>$0.171</money> per share Exercise price unchanged from original awards
Prospectus Supplement regulatory
"This Prospectus Supplement relates to the prospectus dated January 24, 2022"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
selling stockholder financial
"resale by the selling stockholder listed in the Prospectus"
A selling stockholder is an individual or entity that owns shares of a company's stock and chooses to sell some or all of those shares to others. This often occurs when the owner wants to cash in on their investment or reduce their stake. For investors, understanding who the selling stockholder is can provide insights into potential changes in the company's ownership or market activity.
nonqualified stock options compensation
"modification of certain outstanding nonqualified stock options"
A nonqualified stock option is a company-issued right that lets an employee or contractor buy shares later at a preset price, like a coupon to purchase stock regardless of the market price. It matters to investors because when the option is used the recipient owes ordinary-income tax on the difference between market and preset price, which affects the holder’s financial decisions and can change the company’s share count and reported expenses.
share-based compensation charge accounting
"expect to record a one-time non-cash share-based compensation charge"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does ParkerVision's prospectus supplement register (PRKR)?

It registers 1,578,946 shares of Common Stock for resale. This consists of 1,052,631 issued shares and 526,315 shares issuable upon exercise of warrants tied to a December 14, 2021 agreement.

Will ParkerVision receive proceeds from the registered resale (PRKR)?

The company will not receive proceeds from the resale by the selling stockholder. The company would receive up to $526,315 only if the 526,315 Warrants are exercised for cash by their holder.

What executive option changes did ParkerVision disclose (PRKR)?

Options for the CEO and CFO were extended to August 7, 2029. The modification covers 2,660,000 and 870,550 options respectively; exercise price remains $0.171 and no new shares were issued.

Does the prospectus supplement state expected accounting impact (PRKR)?

Yes. The company expects to record a one-time non-cash share-based compensation charge of approximately $360,000 related to the option expiration extensions.

What is the source document referenced in the supplement (PRKR)?

The supplement attaches the Form 8-K filed April 27, 2026. That Form 8-K discloses the option modifications approved April 22, 2026 and related compensation accounting.

Filed pursuant to Rule 424(b)(3)

Registration No. 333-262147

 

PROSPECTUS SUPPLEMENT No. 53

(to Prospectus dated January 24, 2022)

 

PARKERVISION, INC.

1,578,946 Shares of Common Stock

 

This Prospectus Supplement relates to the prospectus dated January 24, 2022, as amended and supplemented from time to time (the “Prospectus”), which permits the resale by the selling stockholder listed in the Prospectus of up to 1,578,946 shares of our common stock, par value $0.01 per share (“Common Stock”) consisting of an aggregate of 1,052,631 shares of Common Stock and 526,315 shares of Common Stock underlying warrants (“Warrants”) issued pursuant to a securities purchase agreement dated December 14, 2021.

 

We will not receive proceeds from the sale of the shares of Common Stock by the selling stockholder. To the extent the Warrants are exercised for cash, we will receive up to an aggregate of $526,315 in gross proceeds.  We expect to use the proceeds received from the exercise of the Warrants, if any, for general working capital purposes, including payment of litigation expenses.

 

This Prospectus Supplement is being filed to update and supplement the information previously included in the Prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 27, 2026.  Accordingly, we have attached the 8-K to this prospectus supplement.  You should read this prospectus supplement together with the prospectus, which is to be delivered with this prospectus supplement.

 

Any statement contained in the Prospectus shall be deemed to be modified or superseded to the extent that information in this Prospectus Supplement modifies or supersedes such statement.  Any statement that is modified or superseded shall not be deemed to constitute a part of the Prospectus except as modified or superseded by this Prospectus Supplement. 

 

This Prospectus Supplement should be read in conjunction with, and may not be delivered or utilized without, the Prospectus.

 

Our Common Stock is listed on the OTCQB Venture Capital Market under the ticker symbol “PRKR.”

 

Investing in our securities involves a high degree of risk. See Risk Factors beginning on page 5 of the Prospectus for a discussion of information that should be considered in connection with an investment in our securities.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or determined whether this Prospectus or Prospectus Supplement is truthful or complete. Any representation to the contrary is a criminal offense.

 

The date of this Prospectus Supplement is April 27, 2026.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):April 22, 2026

 

PARKERVISION, INC.

(Exact Name of Registrant as Specified in Charter)

     

Florida

000-22904

59-2971472

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

   

4446-1A Hendricks Avenue Suite 354, Jacksonville, Florida

32207

(Address of Principal Executive Offices)

(Zip Code)

 

(904) 732-6100

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

None

 

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter.

 

Emerging growth company   ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

 

 

 

Item 5.02(e) Compensatory Arrangements of Certain Officers

 

On April 22, 2026, the Compensation Committee of the Board of Directors (“Committee”) of ParkerVision, Inc. (the “Company”), approved the modification of certain outstanding nonqualified stock options held by its Chief Executive Officer, Jeffrey Parker, and its Chief Financial Officer, Cynthia French, in order to extend the expiration date of the options from August 7, 2026 to August 7, 2029 to preserve the intended long-term incentive value of the awards.

 

The modified options include 2,660,000 options awarded to Mr. Parker and 870,550 options awarded to Ms. French on August 7, 2019, with an exercise price of $0.171 per share and an original term of seven years. The options were fully vested as of the modification date and the Company expects to record a one-time non-cash share-based compensation charge of approximately $360,000 in connection with the modification of these awards.

 

The extension of the expiration date is the only modification made to these awards, and no changes were made to the exercise price, the number of shares subject to the awards, vesting status or any other terms of the awards. No additional securities were issued in connection with the modification.

 

 

 Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit

Description

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

     

Dated: April 27, 2026

   
   

PARKERVISION, INC.

     
   

By /s/ Cynthia French

   

Cynthia French

   

Chief Financial Officer